| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Parasite B. bovis(IC50= 87 μg/mL)
The mode of action of imidocarb is not fully understood, though two mechanisms have been proposed. The first involves interference with the production and/or utilization of polyamines. The second mechanism is the prevention of entry of inositol into erythrocytes containing the parasites, effectively starving the parasite. It also inhibits acetylcholinesterase, leading to elevated acetylcholine levels. |
|---|---|
| ln Vitro |
Imidocarb dipropionate exhibits potent in vitro antiprotozoal activity against Babesia bovis with an IC50 of 0.87 μg/ml. Its activity is assessed in parasite cultures by measuring parasite growth inhibition. The compound's long-lasting activity makes it effective for veterinary use. These in vitro activities confirm its efficacy as an antiprotozoal agent.
|
| ln Vivo |
Horses receive injections of imidocarb dipropionate subcutaneously or intramuscularly (3.4 mg/kg bw) and cattle (2.1 mg/kg bw). Horses may receive up to four doses spaced seventy-two hours apart. After two weeks, a second dose may be administered[1].
In sheep, imidocarb dipropionate (1. 2 mg/kg bw) is also used to treat anaplasmosis and babesiosis[1]. Imidocarb dipropionate's acute oral LD50 in mice ranges from 646 to 723 mg/kg bw[1]. In rats, imidocarb's acute oral LD50 ranges from 454 to 1251 mg/kg bw[1]. In vivo, imidocarb dipropionate is used to treat babesiosis and other protozoal infections in animals. It eliminates blood parasites and provides extended protection. In a splenectomized lamb model of B. ovis infection, imidocarb (1.2 mg/kg) eliminated parasites from the blood. Its long-lasting activity makes it suitable for single-dose administration. |
| Enzyme Assay |
In vitro antiprotozoal assays for imidocarb dipropionate involve measuring its activity against Babesia bovis and other protozoan parasites. Parasites are cultured in erythrocytes and treated with varying concentrations of the compound. Parasite growth is assessed by microscopic examination or by measuring the incorporation of radiolabeled hypoxanthine. The IC50 (0.87 μg/ml for B. bovis) is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for imidocarb dipropionate are conducted in parasite-infected erythrocyte cultures. The compound's effect on parasite entry and growth is assessed. Acetylcholinesterase inhibition can be measured using standard enzymatic assays. These assays help elucidate the compound's mechanism of action and confirm its antiprotozoal activity.
|
| Animal Protocol |
In vivo animal experiments with imidocarb dipropionate are conducted in veterinary species such as cattle, sheep, horses, and dogs, as well as in laboratory animal models of babesiosis. Animals are infected with Babesia parasites and treated with the compound via injection. Parasitemia is monitored by blood smear microscopy, and clinical signs of infection are assessed. Efficacy endpoints include reduction in parasitemia and survival.
|
| ADME/Pharmacokinetics |
Imidocarb dipropionate is administered via injection and has a long duration of action. It has a molecular weight of 479.35 g/mol and a molecular formula of C25H34N6O6? (dipropionate salt). The compound is typically stored at room temperature. Its extended half-life allows for prolonged therapeutic effect, making it suitable for single-dose treatment in veterinary medicine.
|
| Toxicity/Toxicokinetics |
Imidocarb dipropionate is generally well-tolerated in animals at therapeutic doses, but it can cause adverse effects such as injection site reactions and transient salivation. In veterinary use, appropriate withdrawal periods must be observed to ensure food safety. The compound is not approved for human therapeutic use. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
See also: Imidocarb (with active fraction).
Imidocarb dipropionate is an antiprotozoal agent used in veterinary medicine for the treatment of babesiosis and other protozoal infections. It is a carbanilide derivative with a proposed mechanism involving interference with polyamine metabolism and prevention of inositol entry into infected erythrocytes. It is active against B. bovis (IC50 = 0.87 μg/ml) and eliminates blood parasites. It is also known for its long-lasting activity. |
| Molecular Formula |
C25H32N6O5
|
|---|---|
| Molecular Weight |
496.5588
|
| Exact Mass |
496.243
|
| Elemental Analysis |
C, 60.47; H, 6.50; N, 16.92; O, 16.11
|
| CAS # |
55750-06-6
|
| Related CAS # |
5318-76-3 (HCl);55750-06-6 (propionate);27885-92-3;
|
| PubChem CID |
9983292
|
| Appearance |
Solid powder
|
| Density |
1.39g/cm3
|
| Melting Point |
205ºC
|
| LogP |
2.667
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
567
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N([H])C1=C([H])C([H])=C([H])C(=C1[H])C1=NC([H])([H])C([H])([H])N1[H])N([H])C1=C([H])C([H])=C([H])C(=C1[H])C1=NC([H])([H])C([H])([H])N1[H].O([H])C(C([H])([H])C([H])([H])[H])=O.O([H])C(C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
AFGQXWSHYUHHNV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)
|
| Chemical Name |
N,N'-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea, dipropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10.42 mg/mL (~20.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.04 mg/mL (2.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.4 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.04 mg/mL (2.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.4 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.04 mg/mL (2.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0139 mL | 10.0693 mL | 20.1386 mL | |
| 5 mM | 0.4028 mL | 2.0139 mL | 4.0277 mL | |
| 10 mM | 0.2014 mL | 1.0069 mL | 2.0139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
